Myer E C, Morris D L, Adams M L, Brase D A, Dewey W L
Department of Neurology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0211.
J Pediatr. 1987 Nov;111(5):660-6. doi: 10.1016/s0022-3476(87)80239-1.
To gain further insight into the possible role of endogenous opioid peptides in the respiratory difficulties associated with the apnea of infancy and other disorders possibly related to apnea, the levels of beta-endorphin immunoreactivity were measured in the cerebrospinal fluid (CSF) of five groups of infants: (1) infants with proved apnea, (2) infants with histories of an apparent life-threatening event (ALTE), (3) siblings of victims of the sudden infant death syndrome (SIDS), (4) infants with suspected but unproved apnea, and (5) infants undergoing investigation for other acute illnesses. Twenty-two infants considered at risk for an ALTE (groups 1 to 3) had significantly higher CSF beta-endorphin equivalents (88 +/- 7 pg/mL) than did the 22 control patients in groups 4 and 5 (31 +/- 3 pg/mL). Plasma beta-endorphin immunoreactivity, which was also measured in some of the infants, did not correlate with levels in CSF and, in fact, was significantly lower in the groups at risk for an ALTE (50 +/- 9 pg/mL; n = 14) than in the control subjects (80 +/- 6 pg/mL; n = 11). These studies indicate that elevated beta-endorphin immunoreactivity in CSF may be a marker in infants who have apnea and who may be considered at risk for an ALTE.
为了进一步深入了解内源性阿片肽在与婴儿呼吸暂停及其他可能与呼吸暂停相关的疾病所伴发的呼吸困难中可能发挥的作用，我们测定了五组婴儿脑脊液（CSF）中的β-内啡肽免疫反应性水平：（1）确诊为呼吸暂停的婴儿；（2）有明显危及生命事件（ALTE）病史的婴儿；（3）婴儿猝死综合征（SIDS）受害者的兄弟姐妹；（4）疑似但未确诊呼吸暂停的婴儿；（5）因其他急性疾病正在接受检查的婴儿。22名被认为有发生ALTE风险的婴儿（第1至3组）脑脊液中β-内啡肽等效物水平（88±7 pg/mL）显著高于第4组和第5组的22名对照患者（31±3 pg/mL）。我们还对部分婴儿测定了血浆β-内啡肽免疫反应性，其与脑脊液中的水平不相关，事实上，有发生ALTE风险的组（50±9 pg/mL；n = 14）血浆β-内啡肽免疫反应性显著低于对照受试者（80±6 pg/mL；n = 11）。这些研究表明，脑脊液中β-内啡肽免疫反应性升高可能是患有呼吸暂停且可能被认为有发生ALTE风险的婴儿的一个标志物。
